Xadago

Parkinson's Disease
Treatment
2 FDA approvals
20 Active Studies for Xadago

What is Xadago

SafinamideThe Generic name of this drug
Treatment SummarySafinamide is a medication used to treat Parkinson’s disease. It was approved for use in Europe in 2015 and in the United States in 2017.
Xadagois the brand name
Xadago Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xadago
Safinamide
2017
4

Approved as Treatment by the FDA

Safinamide, otherwise known as Xadago, is approved by the FDA for 2 uses including Parkinson's Disease (PD) and Parkinson's Disease .
Parkinson's Disease (PD)
Used in combination with other therapies
Parkinson's Disease
Used in combination with other therapies

Effectiveness

How Xadago works in the bodySafinamide is an effective drug with many ways of working in the body. It blocks certain molecules that cause nerve damage, protects and rescues neurons, and prevents the release of glutamate. These effects make it a safe and effective treatment for many neurological conditions.

When to interrupt dosage

The extent of Xadago is reliant upon the diagnosed issue. The quantity of dosage fluctuates as per the mode of delivery featured in the table beneath.
Condition
Dosage
Administration
Parkinson's Disease
, 50.0 mg, 100.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet

Warnings

Xadago has seventeen contraindications. Individuals dealing with any of the conditions provided in the following table should not take Xadago.Xadago Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Xadago.
Common Xadago Drug Interactions
Drug Name
Risk Level
Description
2,5-Dimethoxy-4-ethylamphetamine
Major
Safinamide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
Major
Safinamide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
Major
Safinamide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
Major
Safinamide may increase the hypertensive activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
Major
The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Safinamide.
Xadago Toxicity & Overdose RiskOverdosing on Abilify can cause involuntary movements, falls, nausea, difficulty sleeping, high blood pressure, dizziness when standing, hallucinations, restlessness or excessive energy, and feeling sick to the stomach.

Xadago Novel Uses: Which Conditions Have a Clinical Trial Featuring Xadago?

45 active studies are currently assessing the potential of Xadago to alleviate the symptoms of Parkinson's Disease.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1

Xadago Reviews: What are patients saying about Xadago?

5Patient Review
2/9/2022
Xadago for Parkinson's Disease
My parent was having a really tough time with Parkinson's and the added tremor, dystonia, and gait problems. Selegiline just made things worse. But Xadago has completely improved everything and restored their ability to walk without pain or difficulty.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xadago

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Xadago used for?

"XADAGO is a prescription medicine used with levodopa and carbidopa to treat adults with Parkinson's disease (PD) who are having "off" episodes. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor."

Answered by AI

What is the best time to take Xadago?

"Xadago should be taken once a day, typically in the morning, on top of a person's regular levodopa medication schedule. Xadago is an inhibitor of monoamine oxidase B (MAO-B)."

Answered by AI

Is there a generic for Xadago?

"As of now, there is no cheaper generic version of Xadago. The most popular form of Xadago is covered by 61% of insurance companies with a co-pay ranging from $60.00 to $75.00. Even so, some pharmacy coupons or cash prices could be lower. Compare MAOIs."

Answered by AI

How much does Xadago cost?

"The cost for Xadago oral tablet 50 mg is around $1,121 for a supply of 30 tablets. This price is for cash paying customers only and does not include insurance plans."

Answered by AI

Clinical Trials for Xadago

Have you considered Xadago clinical trials? We made a collection of clinical trials featuring Xadago, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Xadago clinical trials? We made a collection of clinical trials featuring Xadago, we think they might fit your search criteria.Go to Trials
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Image of Hunter Holmes McGuire VA Medical Center, Richmond, VA in Richmond, United States.

Exoskeleton for Parkinson's Disease

18 - 90
All Sexes
Richmond, VA
Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for eight weeks (16 total visits) and wear the exoskeleton device while walking under the supervision of a trained kinesiotherapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.
Recruiting
Has No Placebo
Hunter Holmes McGuire VA Medical Center, Richmond, VA (+1 Sites)Jessica B Lehosit
Image of Stanford Neuroscience Health Center in Stanford, United States.

STN+NBM DBS for Mild Cognitive Impairment in Parkinson's Disease

21 - 80
All Sexes
Stanford, CA
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled. Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Recruiting
Has No Placebo
Stanford Neuroscience Health CenterHelen M Bronte-Stewart, MD MSE
Have you considered Xadago clinical trials? We made a collection of clinical trials featuring Xadago, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security